Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$454K | -$1.35M | -$8.22M | -$16.1M | -$22.7M | -$30.0M |
| Net income | -$1.15M | -$24.4M | -$8.23M | -$15.4M | -$21.6M | -$29.4M |
| EPS (diluted) | -$0.34 | -$6.64 | -$0.59 | -$0.89 | -$0.76 | -$0.89 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$405K | -$1.59M | -$7.41M | -$11.4M | -$14.6M | -$23.9M |
| Capital expenditures | — | $802.00 | — | $52.1K | $1.18M | $733K |
| Free cash flow | — | -$1.59M | — | -$11.4M | -$15.8M | -$24.7M |
| Share buybacks | — | — | $100.0K | — | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $391K | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Total assets | $540K | $18.2M | $14.9M | $19.9M | $22.9M | $105M |
| Total liabilities | $5.27M | $202K | $1.75M | $3.72M | $9.70M | $11.0M |
| Shareholders' equity | -$4.73M | $18.0M | $13.2M | $16.2M | $13.3M | $93.8M |
| Retained earnings | -$5.37M | -$29.8M | -$38.0M | -$53.4M | -$75.0M | -$104M |
| Shares (wtd avg diluted) | 3.38M | 3.67M | 13.9M | 17.3M | 28.3M | 33.0M |
Every figure is extracted from Immix Biopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.